CA2946115A1 - Methods and compositions for treatment of lipid storage disorders - Google Patents

Methods and compositions for treatment of lipid storage disorders Download PDF

Info

Publication number
CA2946115A1
CA2946115A1 CA2946115A CA2946115A CA2946115A1 CA 2946115 A1 CA2946115 A1 CA 2946115A1 CA 2946115 A CA2946115 A CA 2946115A CA 2946115 A CA2946115 A CA 2946115A CA 2946115 A1 CA2946115 A1 CA 2946115A1
Authority
CA
Canada
Prior art keywords
cells
pkc
npc1
vimentin
bryostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2946115A
Other languages
English (en)
French (fr)
Inventor
Yiannis A. Ioannou
Lawrence ALTSTIEL
David R. Crockford
Sathapana Kongsamut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
TAO Synergies Inc
Original Assignee
Icahn School of Medicine at Mount Sinai
Neurotrope Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai, Neurotrope Bioscience Inc filed Critical Icahn School of Medicine at Mount Sinai
Publication of CA2946115A1 publication Critical patent/CA2946115A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
CA2946115A 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders Abandoned CA2946115A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461981473P 2014-04-18 2014-04-18
US61/981,473 2014-04-18
US201461987360P 2014-05-01 2014-05-01
US61/987,360 2014-05-01
PCT/US2015/025821 WO2015160851A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Publications (1)

Publication Number Publication Date
CA2946115A1 true CA2946115A1 (en) 2015-10-22

Family

ID=54321042

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2946115A Abandoned CA2946115A1 (en) 2014-04-18 2015-04-14 Methods and compositions for treatment of lipid storage disorders

Country Status (9)

Country Link
US (3) US9724328B2 (enExample)
EP (1) EP3131543A4 (enExample)
JP (1) JP2017511387A (enExample)
KR (1) KR20170031653A (enExample)
CN (1) CN107072982A (enExample)
CA (1) CA2946115A1 (enExample)
IL (1) IL248494A0 (enExample)
MX (1) MX2016013680A (enExample)
WO (1) WO2015160851A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109982695A (zh) 2016-08-18 2019-07-05 国立大学法人奈良先端科学技术大学院大学 免疫调节剂
CA3097744A1 (en) * 2018-04-20 2019-10-24 Retrotope, Inc. Stabilized polyunsaturated compounds and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393026A1 (en) 1999-11-30 2001-06-07 Paul A. Wender Bryostatin analogues, synthetic methods and uses
US7256286B2 (en) 1999-11-30 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
CA2490494A1 (en) 2002-07-02 2004-01-15 Blanchette Rockefeller Neurosciences Institute Pkc activation as a means for enhancing sapp.alpha. secretion and improving cognition using bryostatin type compounds
US8497385B2 (en) 2007-08-31 2013-07-30 The Board Of Trustees Of The Leland Stanford Junior University Bryostatin analogues, synthetic methods and uses
WO2009099563A2 (en) 2008-02-05 2009-08-13 Blanchette Rockefeller Neurosciences Institute Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease
EP3403650A3 (en) 2008-07-28 2019-02-13 Blanchette Rockefeller Neurosciences, Institute Pkc-activating compounds for the treatment of neurodegenerative diseases
US20120156180A1 (en) 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
WO2013071282A1 (en) * 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Pkc activators and combinations thereof
JP2017510646A (ja) 2014-03-27 2017-04-13 アルコン、ダニエル・エル． ニーマンピック病を治療するための組成物および方法

Also Published As

Publication number Publication date
US20190201377A1 (en) 2019-07-04
JP2017511387A (ja) 2017-04-20
WO2015160851A1 (en) 2015-10-22
CN107072982A (zh) 2017-08-18
MX2016013680A (es) 2017-07-05
KR20170031653A (ko) 2017-03-21
US20150297559A1 (en) 2015-10-22
US9724328B2 (en) 2017-08-08
EP3131543A4 (en) 2017-12-20
IL248494A0 (en) 2016-12-29
US20170172978A1 (en) 2017-06-22
EP3131543A1 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
Lone et al. 1-Deoxysphingolipids
Renvoisé et al. Reep1 null mice reveal a converging role for hereditary spastic paraplegia proteins in lipid droplet regulation
Jacobs et al. Hepatic CTP: phosphocholine cytidylyltransferase-α is a critical predictor of plasma high density lipoprotein and very low density lipoprotein
Takasugi et al. BACE1 activity is modulated by cell-associated sphingosine-1-phosphate
Sassa et al. A shift in sphingolipid composition from C24 to C16 increases susceptibility to apoptosis in HeLa cells
Suzuki et al. Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse development
Bruce et al. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice
Podbielska et al. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis
JP2016535725A (ja) 脂質異常症の予防または治療のための化合物および該化合物を含む組成物
Tamari et al. PKC activation in Niemann pick C1 cells restores subcellular cholesterol transport
Knapp et al. Decreased free sphingoid base concentration in the plasma of patients with chronic systolic heart failure
Garcia-Gil et al. Nuclear lipids in the nervous system: what they do in health and disease
Deevska et al. Novel interconnections in lipid metabolism revealed by overexpression of sphingomyelin synthase-1
US20190201377A1 (en) Methods and compositions for treatment of lipid storage disorders
Holdaway et al. Alterations in phosphatidylethanolamine metabolism impacts hepatocellular lipid storage, energy homeostasis, and proliferation
Lal et al. Lipid metabolism in age-related musculoskeletal disorders: insights into sarcopenia and osteoporosis
Kitatani et al. Mechanism of inhibition of sequestration of protein kinase C α/βII by ceramide: roles of ceramide-activated protein phosphatases and phosphorylation/dephosphorylation of protein kinase C α/βII on threonine 638/641
Harasim-Symbor et al. Additive effects of dexamethasone and palmitate on hepatic lipid accumulation and secretion
Nakamura et al. Sphingomyelin regulates the activity of secretory phospholipase A2 in the plasma membrane
Yamada et al. Role of canonical and Non-Canonical sphingolipids and their metabolic enzymes in bone health
Baranowski et al. Pioglitazone induces de novo ceramide synthesis in the rat heart
CA2790680A1 (en) Alzheimer's disease-specific alterations of protein kinase c epsilon (pkc-epsilon) protein levels
EP2948433B1 (en) Atglistatin as lipase inhibitor
AU2022283770B2 (en) Cyclic plasmenylethanolamines
US20050182020A1 (en) Ceramide de novo synthesis-based therapeutic and prophylactic methods, and related articles of manufacture

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211123